Johanna Roberts Sells 600 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $300.01, for a total transaction of $180,006.00. Following the completion of the transaction, the executive vice president now owns 66,159 shares of the company’s stock, valued at $19,848,361.59. This trade represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Johanna Roberts also recently made the following trade(s):

• On Tuesday, April 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $269.11, for a total transaction of $161,466.00.
• On Monday, March 3rd, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00.

Penumbra Stock Performance

NYSE PEN opened at $300.50 on Friday. The company has a 50-day simple moving average of $276.99 and a two-hundred day simple moving average of $254.78. Penumbra, Inc. has a 12-month low of $148.00 and a 12-month high of $310.00. The firm has a market cap of $11.64 billion, a price-to-earnings ratio of 883.82, a PEG ratio of 2.83 and a beta of 0.56. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last issued its earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $324.14 million during the quarter, compared to analysts’ expectations of $315.72 million. On average, equities analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. StockNews.com raised Penumbra from a “hold” rating to a “buy” rating in a research note on Thursday. Morgan Stanley raised their price target on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, February 19th. Truist Financial boosted their price objective on Penumbra from $315.00 to $330.00 and gave the stock a “buy” rating in a report on Thursday. BTIG Research reaffirmed a “buy” rating on shares of Penumbra in a research note on Thursday. Finally, Piper Sandler reiterated an “overweight” rating and set a $330.00 target price (up from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $302.40.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. UMB Bank n.a. boosted its position in Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after buying an additional 70 shares during the period. Hurley Capital LLC purchased a new position in Penumbra during the fourth quarter valued at $56,000. Huntington National Bank boosted its stake in Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after acquiring an additional 154 shares in the last quarter. Mather Group LLC. boosted its position in shares of Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after purchasing an additional 208 shares in the last quarter. Finally, Versant Capital Management Inc grew its stake in shares of Penumbra by 893.5% in the first quarter. Versant Capital Management Inc now owns 308 shares of the company’s stock worth $82,000 after acquiring an additional 277 shares during the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.